ReviewFuture medicinal chemistry2017
Current and future developments in the treatment of virus-induced hypercytokinemia.
Review in Future medicinal chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- The effect of artificial saliva on the control of dry mouth: a semi-experimental study on COVID-19 patients under Non-invasive mechanical ventilation.BMC oral health · 2024Trial
- Randomized controlled study of a diagnosis and treatment plan for moderate coronavirus disease 2019 that integrates Traditional Chinese and Western Medicine.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2022Trial
- Article
- In Silico Modeling of Structural Compatibility and Alignment Between Viral Class I Fusion Cores and Human TLR4/MD-2.International journal of molecular sciences · 2026Article
- Clinical Characteristics and Mortality Trends Among COVID-19 Patients During the First Four Waves in Ngaliema Clinic, Democratic Republic of the Congo.Infection and drug resistance · 2025Article
- Altered ACE2 and interferon landscape in the COVID-19 microenvironment correlate with the anti-PD-1 response in solid tumors.Cellular and molecular life sciences : CMLS · 2024Article
- The role of viral infection in implantation failure: direct and indirect effects.Reproductive biology and endocrinology : RB&E · 2024Review
- Review
- Novel Substituted Azoloazines with Anticoagulant Activity.International journal of molecular sciences · 2023Article
- Elevated Level of Circulating but Not Urine S100A8/A9 Identifies Poor COVID-19 Outcomes.ACS infectious diseases · 2023Article
- Article
- An overview on monkeypox virus: Pathogenesis, transmission, host interaction and therapeutics.Frontiers in cellular and infection microbiology · 2023Review
- Survival Analysis of COVID-19 Patients Based on Different Levels of D-dimer and Coagulation Factors.Biomedical and environmental sciences : BES · 2022Article
- Pulmonary Involvement in SARS-CoV-2 Infection Estimates Myocardial Injury Risk.Medicina (Kaunas, Lithuania) · 2022Observational
- D-Dimer as a Sensitive Biomarker of Survival Rate in Patients with COVID-19.The Eurasian journal of medicine · 2022Article
- Inflammatory and thrombotic parameters associated with the COVID-19 course in Poland (SARSTer study).Advances in medical sciences · 2022Article
- Clinical features and mortality of COVID-19 patients admitted to ICU according to SOFA score.Medicine · 2022Article
- Chlorpromazine, a Clinically Approved Drug, Inhibits SARS-CoV-2 Nucleocapsid-Mediated Induction of IL-6 in Human Monocytes.Molecules (Basel, Switzerland) · 2022Article
- Resurrection of an ancient inflammatory locus reveals switch to caspase-1 specificity on a caspase-4 scaffold.The Journal of biological chemistry · 2022Article
- The function of specialized pro-resolving endogenous lipid mediators, vitamins, and other micronutrients in the control of the inflammatory processes: Possible role in patients with SARS-CoV-2 related infection.Prostaglandins & other lipid mediators · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emerging pathogenic viruses such as Ebola and Middle Eastern Respiratory Syndrome coronavirus (MERS-CoV) can cause acute infections through the evasion of the host's antiviral immune responses and by inducing the upregulation of inflammatory cytokines. This immune dysregulation, termed a cytokine storm or hypercytokinemia, is potentially fatal and is a significant underlying factor in increased mortality of infected patients. The prevalence of global outbreaks in recent years has offered opportunities to study the progression of various viral infections and have provided an improved understanding of hypercytokinemia associated with these diseases. However, despite this increased knowledge and the study of the infections caused by a range of emerging viruses, the therapeutic options still remain limited. This review aims to explore alternative experimental strategies for treating hypercytokinemia induced by the Ebola, avian influenza and Dengue viruses; outlining their modes of action, summarizing their preclinical assessments and potential clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.